Disability and rehabilitation. Assistive technology · 2024
Management of FSHD symptoms: current assistive technologies and pharmacological approaches.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hitti George, Kavanaugh Aaron, Zukotynski Brian, Billi Fabrizio
Аннотация
BACKGROUND: Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetically linked disorder characterized by the progressive deterioration of muscles controlling facial and scapular movement. The severity and distribution of affected muscle groups vary significantly across patient demographics, necessitating diverse assistive approaches.
OBJECTIVE: This review aims to evaluate the effectiveness of assistive devices and therapeutic options, including medications and rehabilitative therapies, tailored to specific manifestations of FSHD.
METHODS: An analysis of existing literature and clinical trials was conducted to explore current assistive technologies and pharmacological treatments, focusing on their application to FSHD patients with varying symptom severity.
RESULTS: Although several pharmacological treatments, such as steroids, supplements, protein inhibitors, and knockout strategies, are under investigation, none have yet fully counteracted the disease process driven by toxic DUX4 production. Consequently, the broad assortment of assistive devices currently on the market remain critical for improving quality of life.
CONCLUSION: Despite advances in pharmacological research, the variability in FSHD manifestations necessitates a personalized approach combining assistive technologies and tailored therapeutic interventions. Future research should continue exploring integrative strategies to address the unique needs of FSHD patients.
OBJECTIVE: This review aims to evaluate the effectiveness of assistive devices and therapeutic options, including medications and rehabilitative therapies, tailored to specific manifestations of FSHD.
METHODS: An analysis of existing literature and clinical trials was conducted to explore current assistive technologies and pharmacological treatments, focusing on their application to FSHD patients with varying symptom severity.
RESULTS: Although several pharmacological treatments, such as steroids, supplements, protein inhibitors, and knockout strategies, are under investigation, none have yet fully counteracted the disease process driven by toxic DUX4 production. Consequently, the broad assortment of assistive devices currently on the market remain critical for improving quality of life.
CONCLUSION: Despite advances in pharmacological research, the variability in FSHD manifestations necessitates a personalized approach combining assistive technologies and tailored therapeutic interventions. Future research should continue exploring integrative strategies to address the unique needs of FSHD patients.